Top

Breast Cancer Research and Treatment

Published in:

01-08-2019 | Mastectomy | Epidemiology

The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis

Authors: Helen M. Johnson, William Irish, Nasreen A. Vohra, Jan H. Wong

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Abstract

Purpose

Current NCCN guidelines for occult breast cancer (OBC) recommend modified radical mastectomy, with the option for breast preservation with radiation instead of mastectomy for N1 patients. Our aim was to compare the effect of local therapy—mastectomy versus breast radiation—on breast cancer-specific mortality (BCSM) in a contemporary cohort of OBC patients of all nodal stages.

Methods

Competing risk analyses were performed to evaluate the effect of local therapy, nodal stage, and other demographic and clinical prognostic variables on risk of BCSM for women registered in the SEER database with T0N+M0 breast cancer from 2004 to 2015.

Results

Of the 353 women with OBC who underwent axillary nodal dissection, 152 received breast radiation and 201 underwent mastectomy. Overall, 57.5% had N1 disease, 54.4% had estrogen receptor (ER) positive tumors, 80.7% were white, and 88.1% received chemotherapy. Women treated with radiation were older (p < 0.001). The two groups were comparable with respect to all other variables analyzed. During a median follow-up of 66 months, 32 women died from breast cancer (radiation: 11, mastectomy: 21). Five-year cumulative incidence of BCSM was 8.0% ± 2.6% with radiation versus 10.9% ± 2.6% with mastectomy (p = 0.309). On multivariate analysis, independent predictors of BCSM included older age, higher N stage, and ER negativity, but the type of local therapy was not significantly associated with outcome.

Conclusions

These results suggest that breast preservation is a reasonable alternative to mastectomy for OBC patients, regardless of nodal stage.

Halsted WS (1907) I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46 (1):1–19CrossRefPubMedPubMedCentral

Khandelwal AK, Garguilo GA (2005) Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg 190(4):609–613. https://doi.org/10.1016/j.amjsurg.2005.06.026 CrossRefPubMed

Owen HW, Dockerty MB, Gray HK (1954) Occult carcinoma of the breast. Surg Gynecol Obstet 98(3):302–308PubMed

Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA (1990) Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 125(2):210–214CrossRefPubMed

de Bresser J, de Vos B, van der Ent F, Hulsewé K (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol 36(2):114–119. https://doi.org/10.1016/j.ejso.2009.09.007 CrossRefPubMed

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, version 3. 2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 11 Jan 2019

National Cancer Institute. Overview of the SEER Program. https://seer.cancer.gov/about/overview.html. Accessed 24 July 2018

Surveillance, Epidemiology, and End Results (SEER) Program (https://www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973–2015 varying)—Linked to County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Accessed 24 Aug 2018.

Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA (2010) Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116(17):4000–4006. https://doi.org/10.1002/cncr.25197 CrossRefPubMed

10.

Hessler LK, Molitoris JK, Rosenblatt PY, Bellavance EC, Nichols EM, Tkaczuk KHR, Feigenberg SJ, Bentzen SM, Kesmodel SB (2017) Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol 24(10):2907–2914. https://doi.org/10.1245/s10434-017-5928-x CrossRefPubMed

11.

Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2016) Comparison of SEER treatment data with medicare claims. Med Care 54(9):e55–64. https://doi.org/10.1097/MLR.0000000000000073 CrossRefPubMedPubMedCentral

12.

Gong Y, Liu YR, Ji P, Hu X, Shao ZM (2017) Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 7:45411. https://doi.org/10.1038/srep45411 CrossRefPubMedPubMedCentral

13.

National Cancer Institute. Breast Subtype (2010+). https://seer.cancer.gov/seerstat/databases/ssf/breast-subtype.html. Accessed 24 July 2018

14.

Olson JA, Morris EA, Van Zee KJ, Linehan DC, Borgen PI (2000) Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7(6):411–415CrossRefPubMed

15.

Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR (2006) Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 71(5–6):456–459. https://doi.org/10.1159/000107111 CrossRefPubMed

16.

Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK (2016) Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol 23(6):1838–1844. https://doi.org/10.1245/s10434-016-5104-8 CrossRefPubMed

17.

Lehman CD, DeMartini W, Anderson BO, Edge SB (2009) Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Cancer Netw 7(2):193–201CrossRef

18.

Foroudi F, Tiver KW (2000) Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 47(1):143–147CrossRefPubMed

19.

Shannon C, Walsh G, Sapunar F, A'Hern R, Smith I (2002) Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast 11(5):414–418. https://doi.org/10.1054/brst.2002.0455 CrossRefPubMed

20.

National Comprehensive Cancer Network. Archive NCCN clinical practice guidelines in oncology (NCCN Guidelines^®) for breast cancer V.1.2013.

21.

Stomper PC, Waddell BE, Edge SB, Klippenstein DL (1999) Breast MRI in the evaluation of patients with occult primary breast carcinoma. Breast J 5(4):230–234CrossRefPubMed

22.

Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L (1997) MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 205(2):437–440. https://doi.org/10.1148/radiology.205.2.9356625 CrossRefPubMed

23.

Orel SG, Weinstein SP, Schnall MD, Reynolds CA, Schuchter LM, Fraker DL, Solin LJ (1999) Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 212(2):543–549. https://doi.org/10.1148/radiology.212.2.r99au40543 CrossRefPubMed

24.

Brenner RJ, Rothman BJ (1997) Detection of primary breast cancer in women with known adenocarcinoma metastatic to the axilla: use of MRI after negative clinical and mammographic examination. J Magn Reson Imaging 7(6):1153–1158CrossRefPubMed

25.

Farria DM, Schmidt ME, Monsees BS, Smith RA, Hildebolt C, Yoffie R, Monticciolo DL, Feig SA, Bassett LW (2005) Professional and economic factors affecting access to mammography: a crisis today, or tomorrow? Results from a national survey. Cancer 104(3):491–498. https://doi.org/10.1002/cncr.21304 CrossRefPubMed

26.

Bassett LW, Dhaliwal SG, Eradat J, Khan O, Farria DF, Brenner RJ, Sayre JW (2008) National trends and practices in breast MRI. AJR Am J Roentgenol 191(2):332–339. https://doi.org/10.2214/AJR.07.3207 CrossRefPubMed

27.

Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, Rosenberg MA, Alfisher M, Fletcher SW (2014) Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011. JAMA Intern Med 174(1):114–121. https://doi.org/10.1001/jamainternmed.2013.11958 CrossRefPubMedPubMedCentral

28.

Wernli KJ, DeMartini WB, Ichikawa L, Lehman CD, Onega T, Kerlikowske K, Henderson LM, Geller BM, Hofmann M, Yankaskas BC, Consortium BCS (2014) Patterns of breast magnetic resonance imaging use in community practice. JAMA Intern Med 174(1):125–132. https://doi.org/10.1001/jamainternmed.2013.11963 CrossRefPubMedPubMedCentral

29.

Wu SG, Zhang WW, Sun JY, Li FY, Lin HX, Chen YX, He ZY (2017) Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis. J Cancer 8(18):3849–3855. https://doi.org/10.7150/jca.21217 CrossRefPubMedPubMedCentral

30.

Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ (2005) Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 12(12):1045–1053. https://doi.org/10.1245/ASO.2005.03.520 CrossRefPubMed

31.

McCartan DP, Zabor EC, Morrow M, Van Zee KJ, El-Tamer MB (2017) Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol 24(11):3141–3147. https://doi.org/10.1245/s10434-017-5965-5 CrossRefPubMedPubMedCentral

32.

Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA (2015) Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90–95. https://doi.org/10.1245/s10434-014-3991-0 CrossRefPubMed

33.

Fayanju OM, Stoll CR, Fowler S, Colditz GA, Jeffe DB, Margenthaler JA (2013) Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis. Ann Surg Oncol 20(10):3308–3316. https://doi.org/10.1245/s10434-013-3157-5 CrossRefPubMedPubMedCentral

Title: The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis
Authors: Helen M. Johnson
William Irish
Nasreen A. Vohra
Jan H. Wong
Publication date: 01-08-2019
Publisher: Springer US
Keywords: Mastectomy
Breast Cancer
Breast Cancer
Breast MRI
Published in: Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05285-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Radiation oncology crossword: breast cancer

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database

Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice

Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer